The Korean Journal of Gastroenterology (대한소화기학회지)

The Korean Society of Gastroenterology (대한소화기학회)
권호 표지
DOI QR코드

DOI QR Code

New Helicobacter pylori Eradication Therapies

새로운 헬리코박터 제균 요법

  • Park, Jae Yong (Department of Internal Medicine, Chung-Ang University College of Medicine) ;
  • Kim, Jae Gyu (Department of Internal Medicine, Chung-Ang University College of Medicine)
  • 박재용 (중앙대학교 의과대학 내과학교실) ;
  • 김재규 (중앙대학교 의과대학 내과학교실)
  • Received : 2018.10.01
  • Accepted : 2018.10.29
  • Published : 2018.11.25
⟨ Previous Next ⟩

Abstract

While the prevalence of Helicobacter pylori (H. pylori) infection is decreasing in Korea, the incidence of gastric cancer remains high, emphasizing the importance of H. pylori eradication. A new treatment strategy is needed as the eradication rate with standard triple therapy, which is currently the standard first-line regimen for H. pylori infection, has decreased below the optimum level. The major cause of eradication failure is increased antibiotic resistance. Sequential, concurrent, and hybrid therapies that include clarithromycin produce higher eradication rates than conventional standard triple therapy. However, the effectiveness of these treatments is limited in regions where the resistance rate to various antibiotics is high. Bismuth quadruple therapy is another alternative therapy, but again the eradication rate is not sufficiently high. Tailored therapy based on individual characteristics, including antibiotic susceptibility, may be ideal, but there are several limitations for clinical application and further research is needed. New potassium-competitive acid blocker-based therapies could emerge as effective alternatives in the near future. A consensus is needed to establish a strategy for applying new eradication therapies in Korea.

Keywords

References

  1. Leodolter A, Kulig M, Brasch H, Meyer-Sabellek W, Willich SN, Malfertheiner P. A meta-analysis comparing eradication, healing and relapse rates in patients with Helicobacter pylori-associated gastric or duodenal ulcer. Aliment Pharmacol Ther 2001;15:1949-1958. https://doi.org/10.1046/j.1365-2036.2001.01109.x
  2. Wotherspoon AC, Doglioni C, Diss TC, et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 1993;342:575-577. https://doi.org/10.1016/0140-6736(93)91409-F
  3. Choi IJ, Kook MC, Kim YI, et al. Helicobacter pylori therapy for the prevention of metachronous gastric cancer. N Engl J Med 2018;378:1085-1095. https://doi.org/10.1056/NEJMoa1708423
  4. Korean Helicobacter pylori Study Group. Diagnosis and treatment of Helicobacter pylori infection in Korea. Korean J Gastroenterol 1998;32:275-289.
  5. Kim N, Kim JJ, Choe YH, et al. Diagnosis and treatment guidelines for Helicobacter pylori infection in Korea. Korean J Gastroenterol 2009;54:269-278. https://doi.org/10.4166/kjg.2009.54.5.269
  6. Kim SG, Jung HK, Lee HL, et al. Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised edition. Korean J Gastroenterol 2013;62:3-26. https://doi.org/10.4166/kjg.2013.62.1.3
  7. Asaka M. A new approach for elimination of gastric cancer deaths in Japan. Int J Cancer 2013;132:1272-1276. https://doi.org/10.1002/ijc.27965
  8. Ford AC, Forman D, Hunt R, Yuan Y, Moayyedi P. Helicobacter pylori eradication for the prevention of gastric neoplasia. Cochrane Database Syst Rev 2015;(7):CD005583.
  9. Lee JH, Choi KD, Jung HY, et al. Seroprevalence of Helicobacter pylori in Korea: a multicenter, nationwide study conducted in 2015 and 2016. Helicobacter 2018;23:e12463. https://doi.org/10.1111/hel.12463
  10. Shin WG, Lee SW, Baik GH, et al. Eradication rates of Helicobacter pylori in Korea over the past 10 years and correlation of the amount of antibiotics use: nationwide survey. Helicobacter 2016;21:266-278. https://doi.org/10.1111/hel.12279
  11. Kim BJ, Kim HS, Song HJ, et al. Online registry for nationwide database of current trend of Helicobacter pylori eradication in Korea: interim analysis. J Korean Med Sci 2016;31:1246-1253. https://doi.org/10.3346/jkms.2016.31.8.1246
  12. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010;59:1143-1153. https://doi.org/10.1136/gut.2009.192757
  13. Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol 2017;112:212-239. https://doi.org/10.1038/ajg.2016.563
  14. Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence consensus report. Gut 2017;66:6-30. https://doi.org/10.1136/gutjnl-2016-312288
  15. Fock KM, Katelaris P, Sugano K, et al. Second Asia-Pacific consensus guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol 2009;24:1587-1600. https://doi.org/10.1111/j.1440-1746.2009.05982.x
  16. Zullo A, Rinaldi V, Winn S, et al. A new highly effective short-term therapy schedule for Helicobacter pylori eradication. Aliment Pharmacol Ther 2000;14:715-718. https://doi.org/10.1046/j.1365-2036.2000.00766.x
  17. Rinaldi V, Zullo A, Pugliano F, Valente C, Diana F, Attili AF. The management of failed dual or triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 1997;11:929-933. https://doi.org/10.1046/j.1365-2036.1997.00228.x
  18. Maconi G, Parente F, Russo A, Vago L, Imbesi V, Bianchi Porro G. Do some patients with Helicobacter pylori infection benefit from an extension to 2 weeks of a proton pump inhibitor-based triple eradication therapy? Am J Gastroenterol 2001;96:359-366.
  19. De Francesco V, Margiotta M, Zullo A, et al. Clarithromycin-resistant genotypes and eradication of Helicobacter pylori. Ann Intern Med 2006;144:94-100. https://doi.org/10.7326/0003-4819-144-2-200601170-00006
  20. Jung YS, Park CH, Park JH, Nam E, Lee HL. Efficacy of Helicobacter pylori eradication therapies in Korea: a systematic review and network meta-analysis. Helicobacter 2017;22:e12389. https://doi.org/10.1111/hel.12389
  21. Kim YS, Kim SJ, Yoon JH, et al. Randomised clinical trial: the efficacy of a 10-day sequential therapy vs. a 14-day standard proton pump inhibitor-based triple therapy for Helicobacter pylori in Korea. Aliment Pharmacol Ther 2011;34:1098-1105. https://doi.org/10.1111/j.1365-2036.2011.04843.x
  22. Choi HS, Chun HJ, Park SH, et al. Comparison of sequential and 7-, 10-, 14-d triple therapy for Helicobacter pylori infection. World J Gastroenterol 2012;18:2377-2382. https://doi.org/10.3748/wjg.v18.i19.2377
  23. Chung JW, Jung YK, Kim YJ, et al. Ten-day sequential versus triple therapy for Helicobacter pylori eradication: a prospective, open-label, randomized trial. J Gastroenterol Hepatol 2012;27:1675-1680. https://doi.org/10.1111/j.1440-1746.2012.07249.x
  24. Lam SK, Talley NJ. Report of the 1997 Asia Pacific consensus conference on the management of Helicobacter pylori infection. J Gastroenterol Hepatol 1998;13:1-12. https://doi.org/10.1111/j.1440-1746.1998.tb00537.x
  25. Gatta L, Scarpignato C, Fiorini G, et al. Impact of primary antibiotic resistance on the effectiveness of sequential therapy for Helicobacter pylori infection: lessons from a 5-year study on a large number of strains. Aliment Pharmacol Ther 2018;47:1261-1269. https://doi.org/10.1111/apt.14597
  26. Gong EJ, Ahn JY. Antimicrobial resistance of Helicobacter pylori isolates in Korea. Korean J Helicobacter Up Gastrointest Res 2018;18:82-88. https://doi.org/10.7704/kjhugr.2018.18.2.82
  27. Hwang JJ, Lee DH, Yoon H, Shin CM, Park YS, Kim N. Efficacy of moxifloxacin-based sequential and hybrid therapy for first-line Helicobacter pylori eradication. World J Gastroenterol 2015;21:10234-10241. https://doi.org/10.3748/wjg.v21.i35.10234
  28. Hwang JJ, Lee DH, Lee AR, et al. Efficacy of moxifloxacin-based sequential therapy for first-line eradication of Helicobacter pylori infection in gastrointestinal disease. World J Gastroenterol 2015;21:5032-5038. https://doi.org/10.3748/wjg.v21.i16.5032
  29. Lim JH, Lee DH, Choi C, et al. Clinical outcomes of two-week sequential and concomitant therapies for Helicobacter pylori eradication: a randomized pilot study. Helicobacter 2013;18:180-186. https://doi.org/10.1111/hel.12034
  30. Kim SY, Lee SW, Hyun JJ, et al. Comparative study of Helicobacter pylori eradication rates with 5-day quadruple "concomitant" therapy and 7-day standard triple therapy. J Clin Gastroenterol 2013;47:21-24. https://doi.org/10.1097/MCG.0b013e3182548ad4
  31. Chung JW, Han JP, Kim KO, et al. Ten-day empirical sequential or concomitant therapy is more effective than triple therapy for Helicobacter pylori eradication: a multicenter, prospective study. Dig Liver Dis 2016;48:888-892. https://doi.org/10.1016/j.dld.2016.05.005
  32. Lee HJ, Kim JI, Lee JS, et al. Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies. World J Gastroenterol 2015;21:351-359. https://doi.org/10.3748/wjg.v21.i1.351
  33. Lee JY, Ahn JY, Choi IJ. Historical perspective of Helicobacter pylori treatment in Korea. Korean J Helicobacter Up Gastrointest Res 2015;15:211-221. https://doi.org/10.7704/kjhugr.2015.15.4.211
  34. Gisbert JP, Calvet X, O'Connor A, Megraud F, O'Morain CA. Sequential therapy for Helicobacter pylori eradication: a critical review. J Clin Gastroenterol 2010;44:313-325.
  35. Kang BK, Park SM, Kim BW. New therapeutic strategies against Helicobacter pylori. Korean J Gastroenterol 2014;63:146-150. https://doi.org/10.4166/kjg.2014.63.3.146
  36. Park SM, Kim JS, Kim BW, Ji JS, Choi H. Randomized clinical trial comparing 10- or 14-day sequential therapy and 10- or 14-day concomitant therapy for the first line empirical treatment of Helicobacter pylori infection. J Gastroenterol Hepatol 2017;32:589-594. https://doi.org/10.1111/jgh.13510
  37. Kim SY, Lee SW, Choe JW, et al. Helicobacter pylori eradication rates of concomitant and sequential therapies in Korea. Helicobacter 2017;22:e12441. https://doi.org/10.1111/hel.12441
  38. Bae HJ, Kim JS, Kim BW, Nam YJ. Concomitant or sequential therapy as the first-line therapy for eradication of Helicobacter pylori infection in Korea: a systematic review and meta-analysis. Korean J Gastroenterol 2018;71:31-37. https://doi.org/10.4166/kjg.2018.71.1.31
  39. Gatta L, Vakil N, Vaira D, Scarpignato C. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. BMJ 2013;347:f4587. https://doi.org/10.1136/bmj.f4587
  40. He L, Deng T, Luo H. Meta-analysis of sequential, concomitant and hybrid therapy for Helicobacter pylori eradication. Intern Med 2015;54:703-710. https://doi.org/10.2169/internalmedicine.54.3442
  41. Apostolopoulos P, Koumoutsos I, Ekmektzoglou K, et al. Concomitant versus sequential therapy for the treatment of Helicobacter pylori infection: a Greek randomized prospective study. Scand J Gastroenterol 2016;51:145-151. https://doi.org/10.3109/00365521.2015.1079646
  42. Jang HJ, Choi MH, Kim YS, et al. Effectiveness of triple therapy and quadruple therapy for Helicobacter pylori eradication. Korean J Gastroenterol 2005;46:368-372.
  43. Fischbach L, Evans EL. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther 2007;26:343-357. https://doi.org/10.1111/j.1365-2036.2007.03386.x
  44. Yuan Y, Ford AC, Khan KJ, et al. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev 2013;(12):CD008337.
  45. Lee ST, Lee DH, Lim JH, et al. Efficacy of 7-day and 14-day bismuth-containing quadruple therapy and 7-day and 14-day moxifloxacin-based triple therapy as second-line eradication for Helicobacter pylori infection. Gut Liver 2015;9:478-485. https://doi.org/10.5009/gnl14020
  46. Lee BH, Kim N, Hwang TJ, et al. Bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate in Korea. Helicobacter 2010;15:38-45. https://doi.org/10.1111/j.1523-5378.2009.00735.x
  47. Boyanova L, Mitov I. Geographic map and evolution of primary Helicobacter pylori resistance to antibacterial agents. Expert Rev Anti Infect Ther 2010;8:59-70. https://doi.org/10.1586/eri.09.113
  48. Megraud F, Coenen S, Versporten A, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2013;62:34-42. https://doi.org/10.1136/gutjnl-2012-302254
  49. Hsu PI, Wu DC, Wu JY, Graham DY. Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days. Helicobacter 2011;16:139-145. https://doi.org/10.1111/j.1523-5378.2011.00828.x
  50. Hsu PI, Wu DC, Wu JY, Graham DY. Is there a benefit to extending the duration of Helicobacter pylori sequential therapy to 14 days? Helicobacter 2011;16:146-152. https://doi.org/10.1111/j.1523-5378.2011.00829.x
  51. Oh DH, Lee DH, Kang KK, et al. Efficacy of hybrid therapy as first-line regimen for Helicobacter pylori infection compared with sequential therapy. J Gastroenterol Hepatol 2014;29:1171-1176. https://doi.org/10.1111/jgh.12518
  52. Heo J, Jeon SW, Jung JT, et al. Concomitant and hybrid therapy for Helicobacter pylori infection: a randomized clinical trial. J Gastroenterol Hepatol 2015;30:1361-1366. https://doi.org/10.1111/jgh.12983
  53. Garcia N, Calvet X, Gene E, Campo R, Brullet E. Limited usefulness of a seven-day twice-a-day quadruple therapy. Eur J Gastroenterol Hepatol 2000;12:1315-1318. https://doi.org/10.1097/00042737-200012120-00008
  54. Zhang W, Chen Q, Liang X, et al. Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy. Gut 2015;64:1715-1720. https://doi.org/10.1136/gutjnl-2015-309900
  55. Chen Q, Zhang W, Fu Q, et al. Rescue therapy for Helicobacter pylori eradication: a randomized non-inferiority trial of amoxicillin or tetracycline in bismuth quadruple therapy. Am J Gastroenterol 2016;111:1736-1742. https://doi.org/10.1038/ajg.2016.443
  56. Choe JW, Jung SW, Kim SY, et al. Comparative study of Helicobacter pylori eradication rates of concomitant therapy vs modified quadruple therapy comprising proton-pump inhibitor, bismuth, amoxicillin, and metronidazole in Korea. Helicobacter 2018;23:e12466. https://doi.org/10.1111/hel.12466
  57. Scott DR, Munson KB, Marcus EA, Lambrecht NW, Sachs G. The binding selectivity of vonoprazan (TAK-438) to the gastric H+, K+ -ATPase. Aliment Pharmacol Ther 2015;42:1315-1326. https://doi.org/10.1111/apt.13414
  58. Jenkins H, Sakurai Y, Nishimura A, et al. Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium- competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther 2015;41:636-648. https://doi.org/10.1111/apt.13121
  59. Sakurai Y, Mori Y, Okamoto H, et al. Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects--a randomised open-label cross-over study. Aliment Pharmacol Ther 2015;42:719-730. https://doi.org/10.1111/apt.13325
  60. Sachs G, Scott DR, Wen Y. Gastric infection by Helicobacter pylori. Curr Gastroenterol Rep 2011;13:540-546. https://doi.org/10.1007/s11894-011-0226-4
  61. Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut 2016;65:1439-1446. https://doi.org/10.1136/gutjnl-2015-311304
  62. Maruyama M, Tanaka N, Kubota D, et al. Vonoprazan-based regimen is more useful than PPI-based one as a first-line Helicobacter pylori eradication: a randomized controlled trial. Can J Gastroenterol Hepatol 2017;2017:4385161.
  63. Jung YS, Kim EH, Park CH. Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication. Aliment Pharmacol Ther 2017;46:106-114. https://doi.org/10.1111/apt.14130
  64. Lee JY, Kim N. Future trends of Helicobacter pylori eradication therapy in Korea. Korean J Gastroenterol 2014;63:158-170. https://doi.org/10.4166/kjg.2014.63.3.158
  65. Lee HJ, Kim JI, Cheung DY, et al. Eradication of Helicobacter pylori according to 23S ribosomal RNA point mutations associated with clarithromycin resistance. J Infect Dis 2013;208:1123-1130. https://doi.org/10.1093/infdis/jit287
  66. Chen H, Dang Y, Zhou X, Liu B, Liu S, Zhang G. Tailored therapy versus empiric chosen treatment for Helicobacter pylori eradication: a meta-analysis. Medicine (Baltimore) 2016;95:e2750. https://doi.org/10.1097/MD.0000000000002750
  67. Lopez-Gongora S, Puig I, Calvet X, et al. Systematic review and meta-analysis: susceptibility-guided versus empirical antibiotic treatment for Helicobacter pylori infection. J Antimicrob Chemother 2015;70:2447-2455. https://doi.org/10.1093/jac/dkv155

Cited by

  1. Best Helicobacter pylori Eradication Strategy in the Era of Antibiotic Resistance vol.9, pp.8, 2018, https://doi.org/10.3390/antibiotics9080436